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CORRELATION OF WEIGHT TO CARDIOMETABOLIC RISK AS
IDENTIFIED BY ICD-9 DIAGNOSIS CODES AND
PRESCRIPTIONS IN PRIMARY CARE
Brixner DI, Said Q, Ghate S, McAdam-Marx C
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: This study evaluated the association of patients
with a BMI > 27 kg/m2 vs. a BMI °Y´18 and °Ü27 kg/m2 with car-
diometabolic risk factors (CMRFs). METHODS: A retrospective
review of an Electronic Medical Record database containing
ambulatory health record data for a nationally representative
sample of over 5 million US citizens with a BMI °Y´18 kg/m2 and
°Y´18 years of age was conducted. Patients with a valid BMI were
included and stratiﬁed by no CMRFs or with one or more diag-
noses or prescription orders associated with high triglycerides
(TG), low high density lipoprotein (HDL), type 2 diabetes or
hypertension two years prior to the last observation date.
RESULTS: A total of 499,594 patients were identiﬁed in the
study where 56% (281,988) had a BMI > 27 with a CMRF dis-
tribution of none (49.79%) one (35.36%) two (13.01%), three
(1.70%) or four (0.14%). Of those with one risk factor 141,852
(31.29%) had hypertension, 10,866 (2.90%) had diabetes, 3667
(0.92%) had increased TGs and 1201 (0.26%) had low HDL.
Compared to patients with no risk factors patients with 1–4 risk
factors were signiﬁcantly more likely to be in the >27 kg/m2
group in all cases (p < 0.001). Odds rations were 2.64 for hyper-
tension, 2.21 for elevated triglycerides, 1.91 for diabetes and
1.45 for low HDL; 3.58 for any 2 risk factors, 4.24 for any 3
risk factors and 5.07 for all 4 risk factors, relative to having 
no CMRFs. CONCLUSION: Patients with CMRFs including
hypertension, elevated triglycerides, diabetes or low HDL were
anywhere from 5.07 to 1.45 times more likely to be have a BMI
> 27. Diagnoses and treatments for CMRFs may be used as sur-
rogate measures for the presence of obesity in claims data. Drugs
that decrease both weight and improve CMRFs in such patients
could be beneﬁcial.
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THE RELATIONSHIP BETWEEN OBESITY AND HEALTH-
RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE
TO SEVERE PSORIASIS OR RHEUMATOID ARTHRITIS
Eisenberg DF, Hanlon A, Segal J
Temple University, Philadelphia, PA, USA
OBJECTIVES: To explore the relationship between obesity and
health-related quality of life (HRQoL) in patients with moder-
ate to severe psoriasis (PsO) or rheumatoid arthritis (RA).
METHODS: A retrospective analysis on secondary clinical 
trial assessed 1205 PsO and 1988 RA patients using several
approaches: (1) two univariate regression analyses [obesity pre-
dicting HRQoL; disease severity predicting HRQoL] and (2) a
stepwise multivariate multiple regression analysis (MVA) to
assess obesity as an independent predictor of HRQoL. Disease
severity was measured using the PASI for PsO and DAS for RA.
SF-36 was used for HRQoL assessment in both diseases.
RESULTS: Obesity and disease severity were found to be signif-
icant predictors of HRQoL. The stepwise MVA, using BMI, age,
sex, disease duration and disease severity as predictors, revealed
an overall signiﬁcant effect in the PsO sample [components: L =
0.84, F (10, 2396) = 21.10, p < 0.0001; SF-36 domains: L = 0.73,
F (40, 5198.6) = 9.54, p < 0.0001]. BMI added to the prediction
of HRQoL over PASI for several SF-36 components and
domains: PCS, MCS, PF, RE, SF, VT and MH. The results of the
RA sample were similar: the overall MVA was signiﬁcant [com-
ponents: L = 0.74, F (10, 3962) = 64.05, p < 0.0001; SF-36
domains: L = 0.61, F (40, 8611.9) = 25.81]. Again, BMI added
to the prediction of HRQoL over disease severity for MCS, PF
and VT. Effect sizes in both samples were weak. CONCLUSION:
Obesity was an independent predictor of HRQoL when using
other covariates. This data indicates that reducing BMI and
disease severity contribute signiﬁcantly to the HRQoL of mod-
erate to severe PsO and RA patients.
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HOSPITAL COMPLIANCE WITH ACCP GUIDELINES FOR
ANTICOAGULANT THERAPY AND JCAHO PERFORMANCE
MEASURES
Vats V1, Nutescu EA1,Theobald JC2,Wojtynek JE2, Schumock GT1
1University of Illinois at Chicago, Chicago, IL, USA, 2Consorta Inc,
Schaumburg, IL, USA
OBJECTIVES: To (1) evaluate compliance with American
College of Chest Physicians (ACCP) guidelines for anticoagulant
therapy for prophylaxis or treatment of acute venous throm-
boembolism (VTE), and (2) to assess Joint Commission on
Accreditation of Health care Organizations (JCAHO) perfor-
mance measures for prevention and care of VTE. METHODS:
A retrospective chart review was performed by pharmacists at
32 community hospitals using an online standardized medication
use evaluation form. Compliance with ACCP recommendations
was assessed on the basis of dosage, duration and type of anti-
coagulant used. The following JCAHO performance measures
were calculated using standard deﬁnitions: #5-Objective conﬁr-
mation of clinically suspected VTE, #8-Anticoagulation overlap
of parenteral and warfarin therapy for patients with VTE, #9-
VTE patients with therapeutic International Normalized Ratio
(INR), #10-Platelet count monitoring for patients with VTE
receiving unfractionated heparin (UFH), #11-VTE patients on
warfarin with any INR ratio > 6 during hospitalization, #12-
VTE patients with a calculated creatinine clearance of <30
mL/min that received reduced medication dosage, #13-VTE
treatment for discharged patients with active cancer., #14-UFH
management by nomogram/protocol, and #16-VTE education
(inpatient). Results were expressed as proportions. RESULTS: A
total of 902 cases were assessed. The mean age of the patients
was 67.7 ± 16.9, 385 (42.7%) were males, and 104 (11.5%) had
active cancer. 732 (81.2%) patients received prophylaxis of VTE
while 170 (18.8%) received treatment for acute VTE. The
average length of therapy and hospital stay was 5.7 ± 5.3 and
7.8 ± 7.2 days respectively. Anticoagulant therapy was consis-
tent with ACCP recommendations in 78% of cases. Percent com-
pliance with JCAHO measure #5, #8, #9, #10, #11, #12, #13,
#14 and #16 were 82.9, 67.3, 28.0, 33.5, 0.0, 30.4, 14.7, 96.2,
and 44.3 respectively. CONCLUSION: Anticoagulant therapy
was in compliance with ACCP recommendations in majority of
cases (78%). Performance with some JCAHO measures was less
than optimal. Opportunities exist to improve the prevention and
treatment of VTE.
PQ2
COMPLIANCE AND PERSISTENCE WITH ASTHMA
MEDICATIONS: IMPLICATIONS OF ASTHMA SEVERITY
Cramer JA1, Suh DC2, Chao J3
1Yale University School of Medicine, West Haven, CT, USA, 2Rutgers
University, Piscataway, NJ, USA, 3sanoﬁ-aventis, Bridgewater, NJ, USA
OBJECTIVES: To evaluate differences in medication compliance
and persistence between patients with persistent (HP) and inter-
mittent or non-persistent (HNP) asthma according to the Health
